here are a few recently released papers
Ideggyogy Sz. 2007 Jul 30;60(7-8):301-10.
Investigation of the effect of vinpocetine on cerebral blood flow and cognitive functions]
Valikovics A.
Borsod-Abaúj-Zemplén Megyei Kórház és Egyetemi Oktató Kórház, Neurológia-Toxikológia-Stroke Osztály, Miskolc.
INTRODUCTION: Vinpocetine has been widely used in the treatment of ischaemic cerebrovascular diseases and dementias of vascular type. Chronic cerebral hypoperfusion plays an important role in the development of certain types of dementia. In consequence of complex mode of action vinpocetine plays a significant role in the improvement of cerebral hypoperfusion. The symptoms of mild cognitive impairment considered as "predementia" are similar to those of dementia, although milder. AIMS: The authors investigated the characteristics of the blood flow parameters of patients with ischemic stroke and mild cognitive impairment both in resting conditions or following chemical stimulus as well as they investigated the severity of mental deterioration in the two patient groups. In a pilot study the authors examined the influence of 12-week long oral vinpocetine therapy on the blood flow parameters and cognitive functions in the two patient groups. METHODS: The authors studied the blood flow velocity of a. cerebri media in resting conditions and after 30 sec of breath holding with transcranial Doppler before treatment and after a 12-week long oral vinpocetine treatment. At the same time psychometric tests (MMSE, ADAS-Cog) were used in order to examine cognitive functions, while the general condition of the patients were scored by Clinical Global Impression (CGI) scale. RESULTS: After a 12-week long oral vinpocetine treatment the increase of blood flow velocity in resting conditions compared to the baseline values was significant in the vascular group. The percent increase of mean velocity after the breath holding TCD test showed a significant increase compared to the baseline in both patient groups. The authors found a significant improvement of cognitive functions after a 12-week long oral vinpocetine therapy using psychometric tests. The improvement was identical in both groups. The general condition of patients improved significantly according to both the investigator's and the patients' opinion; patients with mild cognitive impairment judged the improvement higher. CONCLUSIONS: Vinpocetine improved the cerebrovascular reserve capacity in both patient groups and favourably influenced the cognitive status and general condition of patients with chronic hypoperfusion. The authors recommend the use of vinpocetine for the treatment of patients with mild cognitive impairment.
PMID: 17713111 [PubMed - indexed for MEDLINE]
and another
Orv Hetil. 2007 Jul 22;148(29):1353-8.
The role of vinpocetine in the treatment of cerebrovascular diseases based in human studies
[Article in Hungarian]
Bagoly E, Fehér G, Szapáry L.
Pécsi Tudományegyetem, Altalános Orvostudományi Kar Neurológiai Klinika Pécs Rét u 2 7623.
INTRODUCTION: It shows the importance of cerebrovascular diseases that they are the third main cause of death exceeded only by coronary artery diseases and cancer. Cerebral ischemia leads to irreversible brain damage, thereby it is important to rescue the hypoperfused areas. Patients without stroke but with chronic cerebral hypoperfusion can also benefit from the increasing of the cerebral blood flow. METHODS: The aim of this review was to summarize the indications and the potential effects of vinpocetine in acute and chronic cerebrovascular diseases based on clinical studies. RESULTS: There is no evidence that vinpocetine treatment is applicable in acute ischemic stroke, only few study with low patient number showed a slight but significant improvement in the patients conditions. In chronic cerebrovascular patients after single dose and long-term vinpocetine therapy, PET, TCD, SPECT and NIRS examinations showed increasing perfusion and elevated glucose and O 2 consumption of the examined areas, furthermore significant improvement of the rheologic factors was detected. A meta-analysis of international clinical studies showed a significant improvement in cognitive achievement in chronic stroke patients after oral therapy. CONCLUSION: The cited studies showed the potential multi-pharmacological effects of vinpocetine and its beneficial hemorheological potential. The drug also improves the blood flow and the metabolism of the affected brain areas. There is increasing evidence that vinpocetine improves the quality of life in chronic cerebrovascular patients.
PMID: 17631470 [PubMed - indexed for MEDLINE]
Unfortunately these papers were published in hugarian journals I do not have access to hence I cannot comment on dosage.
I can say this.....because I read it here
"Vinpocetine is available as an individual supplement and in combination products. Typical doses for supplement use are 5 to 10 milligrams daily with food. Some take up to 20 milligrams daily. Higher doses are not advised.........
Absorption of vinpocetine is significantly higher when given with food and can be up to about 60% of an ingested dose. On an empty stomach, absorption of an ingested dose can be as low as 7%. Peak plasma levels are obtained one to one and a half hours after ingestion. Extensive metabolism to the inactive apovincaminic acid occurs in the liver. Only small amounts of unmetabolized vinpocetine are excreted in the urine, the major route of excretion of apovincaminic acid. Most of a dose is excreted within 24 hours as this metabolite. The elimination half-life of vinpocetine following ingestion is one to two hours."
so taking 5 mg 3 x per day or with your 3 main meals should keep you topped up.